

Clinical Trial Protocol

Iranian Registry of Clinical Trials

29 May 2026

Comparison of the efficacy of the amoxicillin and pantoprazole regimen with clarithromycin-based quadruple regimen for Helicobacter pylori eradication

Protocol summary

Study aim

Comparison the efficacy of the amoxicillin and pantoprazole regimen with clarithromycin-based quadruple regimen for Helicobacter pylori eradication

Design

This clinical trial with parallel groups, double-blinded randomized, will be conducted on 166 in patients with positive H.pylori infection. Assignment of patients to the study groups will be done by random-numbers table and using computer

Settings and conduct

From patients with confirm diagnosis of H. pylori infection referring to Imam Khomeini hospital, Ahvaz, total of 166 patients will be selected and randomly divided into 2 groups. The patients and experimenters will not know about type of treatment and patient grouping

Participants/Inclusion and exclusion criteria

Inclusion criteria: Age above 18 years, confirm diagnosis of H. pylori infection by stool antigen test, no previous treatment of H. pylori infection, patient consent to participate in the study; Exclusion criteria: using antibiotics or nonsteroidal anti-inflammatory drugs (NSAIDs) in last 4 weeks, allergy to the studied drugs, history of gastric surgery or presence of a serious concomitant disease such as cancer, pregnant or lactating women

Intervention groups

Intervention group (dual regimen): amoxicillin 1000 mg every 12 hours and pantoprazole 40mg every 12 hours for 14 days and then pantoprazole 40 mg every 12 hours for 4 weeks will be prescribed. Control group (quadruple regimen): clarithromycin 500 mg every12 hours, amoxicillin 1000mg every 12 hours, bismuth subcitrate 240 mg every 12 hours and pantoprazole 40 mg every 12 hours for 14 days and then pantoprazole 40 mg every 12 hours for 4 weeks will be prescribed.

Main outcome variables

Presence of Helicobacter pylori infection (based on stool antigen test) 2 weeks after the end of treatment and presence of any complication of medication (nausea, vomiting, and allergic reactions)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20211019052812N1**

Registration date: **2021-11-06, 1400/08/15**

Registration timing: **prospective**

Last update: **2021-11-06, 1400/08/15**

Update count: **0**

Registration date

2021-11-06, 1400/08/15

Registrant information

Name

Samira Mohammadi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 61 3001 3374

Email address

mohammadi.s@ajums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-11-22, 1400/09/01

Expected recruitment end date

2022-04-21, 1401/02/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the efficacy of the amoxicillin and pantoprazole regimen with clarithromycin-based quadruple regimen for Helicobacter pylori eradication

Public title

Comparison the amoxicillin and pantoprazole regimen with quadruple regimen for Helicobacter pylori eradication

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Age more than 18 years Confirm diagnosis of H. pylori infection by stool antigen test No previous treatment of H. pylori infection Patient consent to participate in the study

Exclusion criteria:

Use of antibiotics or nonsteroidal anti-inflammatory drugs (NSAIDs) in the last 4 weeks allergy to any of the studied drugs History of gastric surgery or the presence of a serious concomitant disease such as cancer, Pregnant or lactating women

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Outcome assessor
- Data analyser

Sample size

Target sample size: **166**

Randomization (investigator's opinion)

Randomized

Randomization description

Patients will be assigned into two groups by simple randomization method. Allocation of patients to the study groups will be done by random-numbers table and using computer, and on this basis patients will be included in one of the two treatment groups. The implementation of the random allocation sequence occurs without knowledge of which patient will receive which treatment.

Blinding (investigator's opinion)

Double blinded

Blinding description

Intervention (receiving dual therapy regimen or clarithromycin-based quadruple regimen) and patient evaluation will be carried out by a physician who is blinded to placement in treatment groups. Also patients and statistical analyzer will not know about patient

grouping.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Ahvaz Jundishapur University of Medical Sciences

Street address

Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd.

City

Ahvaz

Province

Khuzestan

Postal code

6135733118

Approval date

2021-10-19, 1400/07/27

Ethics committee reference number

IR.AJUMS.HGOLESTAN.REC.1400.098

Health conditions studied**1****Description of health condition studied**

Helicobacter pylori infection

ICD-10 code

B96.81

ICD-10 code description

Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Primary outcomes**1****Description**

Presence of Helicobacter pylori infection

Timepoint

Two weeks after the end of treatment

Method of measurement

Assess the presence of infection based on Stool Antigen Test

Secondary outcomes

1

Description

Treatment complication

Timepoint

Patients clinical visits every two weeks and follow up by phone call every week

Method of measurement

Presence of nausea, vomiting and any allergic reactions based on clinical information

Intervention groups

1

Description

Intervention group: (dual regimen): amoxicillin 1000 mg every 12 hours (Farabi pharmaceutical CO., Iran) and pantoprazole 40 mg every 12 hours (Tehranchemie CO., Iran) for 14 days and then pantoprazole 40 mg every 12 hours for 4 weeks will be prescribed for Helicobacter pylori eradication.

Category

Treatment - Drugs

2

Description

Control group: (quadruple regimen): clarithromycin (Loghman pharmaceutical CO., Iran) 500 mg every 12 hours, amoxicillin 1000 mg every 12 hours (Farabi pharmaceutical CO., Iran), bismuth subcitrate (Aria Co., Iran) 240 mg every 12 hours and pantoprazole 40 mg every 12 hours (Tehranchemie CO., Iran) for 14 days and then pantoprazole 40 mg every 12 hours for 4 weeks will be prescribed for Helicobacter pylori eradication.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Imam Khomeini Hospital

Full name of responsible person

Samira Mohammadi

Street address

Imam Khomeini Hospital, Azadegan St.

City

Ahvaz

Province

Khouzestan

Postal code

6193673111

Phone

+98 21 3222 2818

Email

mohammadi.s@ajums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Mohammad Baddvi

Street address

Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd.

City

Ahvaz

Province

Khouzestan

Postal code

6135733118

Phone

+98 61 3373 8383

Email

badavim@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Ahvaz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Samira Mohammadi

Position

Resident

Latest degree

Specialist

Other areas of specialty/work

Internal Medicine

Street address

Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd.

City

Ahvaz

Province

Khouzestan

Postal code

6135733118

Phone

+98 61 3001 3374

Fax

Email

mohammadi.s@ajums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Samira Mohammadi

Position

Resident

Latest degree

Specialist

Other areas of specialty/work

Internal Medicine

Street address

Ahvaz Jundishapur University of Medical Sciences,
Golestan Blvd.

City

Ahvaz

Province

Khouzestan

Postal code

6135733118

Phone

+98 61 3001 3374

Fax

Email

mohammadi.s@ajums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Samira Mohammadi

Position

Resident

Latest degree

Specialist

Other areas of specialty/work

Internal Medicine

Street address

Ahvaz Jundishapur University of Medical Sciences,
Golestan Blvd.

City

Ahvaz

Province

Khouzestan

Postal code

6135733118

Phone

+98 61 3001 3374

Fax

Email

mohammadi.s@ajums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available